Edwards Lifesciences Corporation $EW Position Increased by First Trust Advisors LP

First Trust Advisors LP boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 106.9% in the first quarter, Holdings Channel.com reports. The firm owned 352,315 shares of the medical research company’s stock after purchasing an additional 182,047 shares during the period. First Trust Advisors LP’s holdings in Edwards Lifesciences were worth $28,213,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $27,000. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth approximately $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $83.69 on Wednesday. The firm has a fifty day simple moving average of $87.77 and a 200-day simple moving average of $83.85. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The stock has a market capitalization of $48.19 billion, a price-to-earnings ratio of 48.10, a PEG ratio of 2.09 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on EW shares. Mizuho raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research report on Wednesday, April 1st. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.